Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Share-based Compensation (2016 - 2017)

Tenax Therapeutics' Share-based Compensation history spans 7 years, with the latest figure at $79589.0 for Q4 2017.

  • For Q4 2017, Share-based Compensation rose 38914.22% year-over-year to $79589.0; the TTM value through Dec 2017 reached $79589.0, up 7394.26%, while the annual FY2025 figure was $18.8 million, 1571.11% up from the prior year.
  • Share-based Compensation for Q4 2017 was $79589.0 at Tenax Therapeutics, up from -$79525.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $1.4 million in Q1 2014 and bottomed at -$79525.0 in Q3 2017.
  • The 5-year median for Share-based Compensation is $14840.0 (2014), against an average of $194468.9.
  • The largest YoY upside for Share-based Compensation was 38914.22% in 2017 against a maximum downside of 28003.51% in 2017.
  • A 5-year view of Share-based Compensation shows it stood at $13261.0 in 2013, then skyrocketed by 162.94% to $34868.0 in 2014, then crashed by 99.23% to $268.0 in 2015, then fell by 23.88% to $204.0 in 2016, then skyrocketed by 38914.22% to $79589.0 in 2017.
  • Per Business Quant, the three most recent readings for TENX's Share-based Compensation are $79589.0 (Q4 2017), -$79525.0 (Q3 2017), and $79525.0 (Q2 2017).